Literature DB >> 22310943

The impact of plasma fibrinogen levels on patients with vulvar cancer.

Veronika Seebacher1, Stephan Polterauer, Christoph Grimm, Clemens Tempfer, Katrin Hefler-Frischmuth, Alexander Reinthaller, Lukas Hefler.   

Abstract

OBJECTIVE: To investigate the association between plasma fibrinogen levels and clinico-pathological parameters of patients with vulvar cancer and to determine their value as prognostic parameters. STUDY
DESIGN: In this retrospective study, we evaluated pretreatment plasma fibrinogen levels in 120 patients with invasive squamous cell vulvar cancer and correlated them with clinico-pathological parameters and patients' survival.
RESULTS: Pretreatment plasma fibrinogen levels were directly associated with tumor stage (pT1a vs. pT1b vs. pT2 vs. pT3-4, p=0.001), lymph node involvement (pN0 vs. pN1, p=0.04), and histological grade (G1 vs. G2 vs. G3, p=0.03), but not with patients' age (≤ 70 years vs. >70 years, p=0.6). In a multivariate survival analysis, tumor stage (p=0.006/p=0.02) and lymph node involvement (p<0.001/p<0.001), but neither histological grade (p=0.2/p=0.9) nor plasma fibrinogen levels (p=0.6/p=0.6) were associated with disease-free and overall survival, respectively. In a multivariate analysis, patient's age (≤ 70 years vs. >70 years) was associated with overall survival (p=0.03) but not with disease-free survival (p=0.1).
CONCLUSION: Pretreatment plasma fibrinogen levels were directly associated with tumor stage, lymph node involvement and histological grade. Although we could demonstrate a prognostic value of pretreatment plasma fibrinogen levels on survival, we were unable to establish fibrinogen as an independent prognostic parameter in patients with vulvar cancer. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310943     DOI: 10.1016/j.ejogrb.2011.11.030

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  6 in total

Review 1.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

2.  Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Wheel Balance Cancer Therapy.

Authors:  Hwi-Joong Kang; Kyeore Bae; Jee-Hye Kim; Chong-Kwan Cho; Hwa-Seung Yoo
Journal:  Integr Cancer Ther       Date:  2017-07-17       Impact factor: 3.279

3.  Prognostic value of serum creatine level in patients with vulvar cancer.

Authors:  Richard Schwameis; Magdalena Postl; Christine Bekos; Lukas Hefler; Alexander Reinthaller; Veronika Seebacher; Christoph Grimm; Stephan Polterauer; Samir Helmy-Bader
Journal:  Sci Rep       Date:  2019-07-31       Impact factor: 4.379

4.  Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery.

Authors:  Christine Bekos; Stephan Polterauer; Veronika Seebacher; Thomas Bartl; Elmar Joura; Alexander Reinthaller; Alina Sturdza; Reinhard Horvat; Richard Schwameis; Christoph Grimm
Journal:  Arch Gynecol Obstet       Date:  2019-08-29       Impact factor: 2.344

5.  Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.

Authors:  B Ghanim; M A Hoda; T Klikovits; M-P Winter; A Alimohammadi; M Grusch; B Dome; M Arns; P Schenk; M Jakopovic; M Samarzija; L Brcic; M Filipits; V Laszlo; W Klepetko; W Berger; B Hegedus
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

6.  Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study.

Authors:  Christine Bekos; Christoph Grimm; Thomas Brodowicz; Edgar Petru; Lukas Hefler; Daniel Reimer; Horst Koch; Alexander Reinthaller; Stephan Polterauer; Mariella Polterauer
Journal:  Sci Rep       Date:  2017-11-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.